Abstract
Objective: The purpose of this study was to determine the prognostic value of atheromatic markers in the cardiovascular outcome of hypertensive patients. Design and method: We studied 711 hypertensive patients (age 56 ± 13 year old, 47,8% men) under treatment and without (mean systolic/diastolic blood pressure: 149,3 ± 21/92,8 ± 12,7 mmHg, mean Heart rate: 76 ± 12 bpm). The mean follow up was 9,5 ± 6 years. Serum lipid levels, apolipoprotein B/apolipoprotein A1 (apoB/apoA1) and total cholesterol/HDL cholesterol (TChol/HDL) markers were measured in all patients at the beginning of the study. Additionally, the prognostic value in the incidence of major cardiovascular events (MI, stroke, aortic syndromes, cardiovascular death) was evaluated. Results: 59,3% (273 patients) of the total population of the study had a major cardiovascular event. The prognostic value of atheromatic markers in the outcome is presented in the following tables:Conclusions: ApoB/apoA1 and nonHDL-C, but not TChol/HDL Chol were found to bear significant prognostic value for the cardiovascular outcome of hypertensive patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
